NCT04656275View on ClinicalTrials.gov

A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

December 20, 2021

Study Completion Date

January 19, 2022

Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
DRUG

BI 1323495

BI 1323495

DRUG

Placebo

Placebo

Trial Locations (3)

22927

Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf

23552

KLB Gesundheitsforschung Lübeck GmbH, Lübeck

60596

IKF Pneumologie GmbH & Co. KG, Frankfurt

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04656275 - A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation | Biotech Hunter | Biotech Hunter